Assertio Holdings, Inc. (ASRT) — SEC Filings

Latest SEC filings for Assertio Holdings, Inc. (ASRT), explained in plain English.

Sentiment Overview: 1 bullish, 2 bearish, 31 neutral, 2 mixed

Recent Filings (36)

• SC14D9C Filing — SC14D9C · 2026-04-09T08:11:45-04:00 [neutral]
• Assertio Holdings Files 8-K: Material Agreement & Officer Changes — 8-K · 2026-04-09T08:07:14-04:00 [neutral] Risk: medium
  Assertio Holdings, Inc. filed an 8-K on April 9, 2026, reporting a material definitive agreement and changes in directors or officers. The filing also includes
• 8-K Filing — 8-K · 2025-12-22T00:00:00.000Z [neutral]
• 8-K Filing — 8-K · 2025-11-21T00:00:00.000Z [neutral]
• Assertio's Q3 Sales Surge on ROLVEDON, But Divestiture Drags YTD Net Loss — 10-Q · 2025-11-10T00:00:00.000Z [mixed] Risk: medium
  Assertio Holdings, Inc. reported a significant increase in product sales, net, to $49.46 million for the three months ended September 30, 2025, up from $28.71 m
• Assertio Holdings Reports Officer/Director Changes & Compensation — 8-K · 2025-10-30T00:00:00.000Z [neutral] Risk: medium
  Assertio Holdings, Inc. filed an 8-K on October 30, 2025, reporting events as of October 27, 2025. The filing indicates changes related to the departure of dire
• Assertio Holdings Enters Material Definitive Agreement — 8-K · 2025-10-10T00:00:00.000Z [neutral] Risk: medium
  Assertio Holdings, Inc. entered into a material definitive agreement on October 7, 2025. The filing does not disclose the specific details of this agreement, on
• Assertio Q2 Revenue Plunges 23% Amidst Product Sales Decline — 10-Q · 2025-08-11T00:00:00.000Z [bearish] Risk: high
  Assertio Holdings, Inc. reported a significant decline in revenue and net income for the second quarter and first half of 2025. Total revenue for Q2 2025 was $2
• Assertio Holdings Files 8-K on Director Changes and Shareholder Votes — 8-K · 2025-05-13T00:00:00.000Z [neutral] Risk: low
  Assertio Holdings, Inc. filed an 8-K on May 7, 2025, reporting on the departure of a director, the election of new directors, and the appointment of certain off
• Assertio Holdings Files 8-K on Financials — 8-K · 2025-05-12T00:00:00.000Z [neutral] Risk: low
  Assertio Holdings, Inc. filed an 8-K on May 12, 2025, reporting on its results of operations and financial condition. The filing includes financial statements a
• Assertio Holdings Files Definitive Proxy Statement — DEF 14A · 2025-04-08T00:00:00.000Z [neutral] Risk: low
  Assertio Holdings, Inc. filed its definitive proxy statement (DEF 14A) on April 8, 2025, for its annual meeting on May 7, 2025. The filing concerns the solicita
• Assertio Holdings Files 2024 10-K — 10-K · 2025-03-12T00:00:00.000Z [neutral] Risk: medium
  Assertio Holdings, Inc. filed its 2024 10-K on March 12, 2025, reporting on its fiscal year ending December 31, 2024. The company, operating in pharmaceutical p
• Assertio Holdings Faces Listing Rule Concerns — 8-K · 2025-01-28T00:00:00.000Z [neutral] Risk: medium
  Assertio Holdings, Inc. filed an 8-K on January 28, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard, with the e
• Assertio Holdings Announces Board and Executive Changes — 8-K · 2024-12-17T00:00:00.000Z [neutral] Risk: medium
  Assertio Holdings, Inc. announced on December 12, 2024, changes in its board of directors and executive compensation arrangements. The filing details the depart
• SC 13G/A Filing — SC 13G/A · 2024-11-14T00:00:00.000Z [neutral]
• Assertio Holdings Files Q3 2024 10-Q — 10-Q · 2024-11-12T00:00:00.000Z [neutral] Risk: medium
  Assertio Holdings, Inc. filed its 10-Q for the period ending September 30, 2024. The filing covers the third quarter and the first nine months of the year. Key
• SC 13G/A Filing — SC 13G/A · 2024-11-12T00:00:00.000Z [neutral]
• SC 13G/A Filing — SC 13G/A · 2024-11-04T00:00:00.000Z [neutral]
• Assertio Holdings Files Q2 2024 10-Q — 10-Q · 2024-08-07T00:00:00.000Z [neutral] Risk: medium
  Assertio Holdings, Inc. filed its 10-Q for the period ending June 30, 2024. The filing covers the second quarter and first half of the fiscal year. Key financia
• SC 13G/A Filing — SC 13G/A · 2024-07-08T00:00:00.000Z [neutral]
• Assertio Holdings Reports Director Changes & Corporate Updates — 8-K · 2024-05-30T00:00:00.000Z [neutral] Risk: medium
  Assertio Holdings, Inc. filed an 8-K on May 23, 2024, reporting on several key events. These include the departure of directors, election of new directors, appo
• Assertio Holdings Appoints New Chief Medical Officer — 8-K · 2024-05-29T00:00:00.000Z [neutral] Risk: low
  Assertio Holdings, Inc. announced on May 16, 2024, the appointment of Dr. Robert L. Diamond as Chief Medical Officer and Executive Vice President. Dr. Diamond p
• Assertio Holdings, Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · 2024-05-06T00:00:00.000Z [neutral] Risk: medium
  Assertio Holdings, Inc. (ASRT) filed a Quarterly Report (10-Q) with the SEC on May 6, 2024. Assertio Holdings, Inc. reported financial results for the quarter e
• Assertio Holdings, Inc. Announces Virtual Annual Meeting of Stockholders on May 23, 2024 — DEF 14A · 2024-04-19T00:00:00.000Z [neutral] Risk: low
  Assertio Holdings, Inc. (ASRT) filed a Proxy Statement (DEF 14A) with the SEC on April 19, 2024. The Annual Meeting of Stockholders for Assertio Holdings, Inc.
• Assertio Holdings Appoints New CMO, Adds Directors — 8-K · 2024-04-02T00:00:00.000Z [neutral] Risk: medium
  Assertio Holdings, Inc. announced on March 27, 2024, the appointment of Dr. Robert L. Diamond as Chief Medical Officer and the election of Dr. Diamond and Ms. J
• Assertio to Acquire Spectrum Pharma for $1.04B — 8-K · 2024-03-27T00:00:00.000Z [bullish] Risk: medium
  Assertio Holdings, Inc. announced on March 26, 2024, that it has entered into a definitive agreement to acquire all of the outstanding shares of Spectrum Pharma
• Assertio Holdings Files 8-K/A Amendment — 8-K/A · 2024-03-12T00:00:00.000Z [neutral] Risk: low
  Assertio Holdings, Inc. filed an 8-K/A on March 12, 2024, to amend its previous filing regarding results of operations and financial condition, as well as finan
• Assertio Holdings, Inc. Files 2023 Annual Report on Form 10-K — 10-K · 2024-03-11T00:00:00.000Z [neutral] Risk: medium
  Assertio Holdings, Inc. (ASRT) filed a Annual Report (10-K) with the SEC on March 11, 2024. Assertio Holdings, Inc. reported its fiscal year 2023 results on Mar
• Assertio Holdings Faces Potential Delisting or Listing Transfer — 8-K · 2024-02-23T00:00:00.000Z [bearish] Risk: high
  Assertio Holdings, Inc. filed an 8-K on February 23, 2024, reporting an event on February 21, 2024, regarding a 'Notice of Delisting or Failure to Satisfy a Con
• SC 13G/A Filing — SC 13G/A · 2024-02-14T00:00:00.000Z [neutral]
• SC 13G Filing — SC 13G · 2024-02-14T00:00:00.000Z [neutral]
• SC 13G/A Filing — SC 13G/A · 2024-02-14T00:00:00.000Z [neutral]
• SC 13G Filing — SC 13G · 2024-02-13T00:00:00.000Z [neutral]
• Assertio 8-K Signals Major Corporate Event, Multiple Rule Filings — 8-K · 2024-01-26T00:00:00.000Z [mixed]
  Assertio Holdings, Inc. filed an 8-K on January 26, 2024, reporting an event that occurred on January 24, 2024. This filing indicates that the company is using
• BlackRock Discloses Passive Stake in Assertio Holdings (ASRT) — SC 13G · 2024-01-26T00:00:00.000Z [neutral]
  BlackRock Inc., a major investment firm, filed an SC 13G on January 26, 2024, disclosing its ownership of Assertio Holdings, Inc. common stock as of December 31
• Assertio Holdings Reports Officer/Director Changes, Comp Arrangements — 8-K · 2024-01-05T00:00:00.000Z [neutral]
  Assertio Holdings, Inc. filed an 8-K on January 5, 2024, reporting an event that occurred on January 2, 2024. This filing indicates changes related to the depar